Cetraxate (INN) is an oral gastrointestinal medication which has a cytoprotective effect.[1][2][unreliable medical source?]

Synthesis

Cetraxate is a prodrug of tranexamic acid. The latter is a hemostatic agent because it inhibits the activation of plasminogen to plasmin. The result is to prevent excess loss of blood in gastrointestinal ulcers. The synthesis begins with the esterification of 3-(p-hydroxyphenyl)propionic acid (2) by trans-4-cyanocyclohexanecarbonyl chloride (1). The product (3) is reduced to cetraxate (4) by catalytic hydrogenation with hydrogen and Raney nickel.[3][4]

Cetraxate synthesis

References

  1. ^ Kurebayashi Y, Ikeda T, Osada Y (January 1988). "Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats". Japanese Journal of Pharmacology. 46 (1): 17–25. doi:10.1254/jjp.46.17. PMID 3367546.
  2. ^ Ishimori A, Yamagata S, Taima T (1979). "Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study". Arzneimittel-Forschung. 29 (10): 1625–1632. PMID 391240.
  3. ^ Japan Kokai, 59/134,758 (1984)
  4. ^ Svahn CM, Merenyi F, Karlson L, Widlund L, Grälls M (April 1986). "Tranexamic acid derivatives with enhanced absorption". Journal of Medicinal Chemistry. 29 (4): 448–453. doi:10.1021/jm00154a004. PMID 3959024.
Allikas: https://en.wikipedia.org/wiki/Cetraxate
No tags for this post.